Arsanis, Inc. Nominates Preclinical Candidate for Staphylococcus aureus Program
5/23/2013 11:05:35 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VIENNA--(BUSINESS WIRE)--Arsanis Biosciences GmbH, a biotechnology company developing anti-infective human monoclonal antibodies, achieved a major milestone by nominating the preclinical development candidates for its lead program, a monoclonal antibody cocktail to prevent and treat severe hospital associated S. aureus infections.
Help employers find you! Check out all the jobs and post your resume.
comments powered by